|
Stock Profiler.US: Stock Watch: Energy Companies: BLVT, CCEL, AKYI, GTF
(M2 PressWIRE Via Acquire Media NewsEdge) New York, NY -- Bulova Technologies Group, Inc. (Pink Sheets: BLVT); Cryo-Cell International, Inc. (OTCBB:CCEL); AccessKey IP, Inc., (OTCBB:AKYI); Cytomedix, Inc. (NYSE Amex: GTF)
StockProfiler.US is Introducing Leading Microcap Companies! We welcome Investors to sign up and subscribe to our FREE Newsletter at www.stockprofiler.us. Please follow our thread on www.twitter.com at StockProfilerUS
-------------------------------------------
Bulova Technologies Group, Inc. closed at $0.4599 Wednesday, trading 244,064 shares.
Company News- October 15, 2009: Bulova Technologies Group, Inc. Provides Update
Bulova Technologies Group, Inc. (Pink Sheets: BLVT) ("BulovaTech" or "the Company") announced earlier today that it has adopted September 30th as its fiscal year end. The Company's primary business is defense contracting, and September 30 coincides with the end of the government's fiscal year.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About Bulova Technologies Group, Inc.
Headquartered in Clearwater Florida, Bulova Technologies Group, Inc. operates two facilities, Bulova Technologies Ordnance Systems in Mayo, FL and BT Manufacturing Company in Melbourne, FL. The headquarters also houses BulovaTech Labs, Inc. and Bulova Technologies Combat Systems Company which is a world leader in the international sale of military vehicles, weapons and munitions in support of the U.S. Department of Defense.
-------------------------------------------
Cryo-Cell International, Inc. closed at $2.18 Wednesday, trading 20,746 shares.
Company News- October 15, 2009: Cryo-Cell Announces C'elle(SM) Technology License Agreement With Cryopraxis Cryobiology Ltd.
Cryo-Cell International, Inc. (OTCBB:CCEL) ("Company") announced earlier today that it has signed an exclusive technology license agreement with Cryopraxis Cryobiology Ltd. ("Cryopraxis"), a privately-held global regenerative technology leader located in Rio De Janeiro, Brazil.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About Cryo-Cell International, Inc. (OTCBB:CCEL)
Based in Oldsmar, Florida, with nearly 185,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235), or visit www.cryo-cell.com.
-------------------------------------------
AccessKey IP, Inc. closed at $0.0052 Wednesday, trading 195,900 shares.
Company News- October 15, 2009: AccessKey IP, Inc. Announces Funding Transaction
AccessKey IP, Inc., (OTCBB:AKYI) the developer, designer and producer of advanced entertainment and communication devices, announced earlier today that it has entered into a long term financing agreement.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About AccessKey IP, Inc.
AccessKey IP, Inc. is a developer of cutting-edge technologies and best-of-breed products tailored to address the market opportunities created by the explosive growth of digital communications, entertainment-related services and specific consumer electronics platforms. AccessKey IP's AccessKey(TM) products, powered by the Company's patented technology, provide complete access to the coveted "Triple Play" Set Top Box (voice, video and data) and "Quadruple Play" Set Top Box (voice, video, data and wireless) offerings of cable, telecom, satellite and broadband service providers. The Company's AccessKey Home(TM) and portable flash drive-sized AccessKey PC(TM) allow subscribers to "channel surf" streaming "HD Quality" television content (IPtv), navigate the internet, watch Video on Demand (VOD) offerings, play video or internet-based games, listen to music, make phone calls (VoIP), video conference, run a full array of computing applications, securely store data and more, all from a single device and service provider network. Its wholly owned subsidiary TeknoCreations was founded to participate in the explosive growth of Consumer Electronics and Business security needs. TeknoCreations designs high quality products with attractive pricing to enhance the consumer's favorite electronics products and the expanding security needs of corporate America.
-------------------------------------------
Cytomedix, Inc. closed at $0.56 Wednesday, trading 28,163 shares.
Company News- October 15, 2009: Cytomedix to Present At Growth Stock Conference Hosted by Security Research Associates, Inc.
Cytomedix, Inc. (NYSE Amex: GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Martin Rosendale, Chief Executive Officer of Cytomedix, will be presenting a corporate update at Security Research Associates' Growth Stock Conference on Monday, October 19th at 4:00 p.m. (Eastern Time) at the Omni Hotel in New York, New York.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About Cytomedix
Cytomedix develops, sells and licenses regenerative biological therapies including the AutoloGel(TM) System, a device for the production of Platelet Rich Plasma ("PRP") gel derived from the patient's own blood. The AutoloGel(TM) System is cleared by the U.S. Food and Drug Administration for use on a variety of exuding wounds. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGel(TM) System. The Company is also moving forward with the development of other product candidates in its pipeline. Most notably is its CT-112 product, an anti-inflammatory peptide that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.
------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division includes but is not limited to: www.stockprofiler.us; www.associatesfortune.com; www.fastmoneytalk.com; www.markettelegraph.com; www.thewallstreetleader.com; and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To it.tmcnet.com's Homepage ]
|